Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (172)	3/1/2002 7:05:43 AM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 508

"IJ may not think the acquisition of another property is so hot at this time" That is not quite the way I see it. I believe that businesses need to be opportunistic. IF there is a drug that is TOO good to pass up - inlicense it. The Infergen deal was amazing to me. It COULD be very big for ITMN. Actimunne deserves lots of attention but Infergen could be so good that it made sense to add it, do the financing and bring that drug along. Managment has done very well - so far. The Infergen deal also constitutes a strong endorsement of ITMN by AMGN. I also think the fact they are selling shares rather than converts is a sign of the strength of the deal. I hope management does not take on too much. The bottom line is I will wait to see what they are onto. On the last financing I added at about 30. I will be watching again to see how far down they take it. I don't think it will hit 30 this time. Time will tell. ij